[CQM-5367] STK-72 Alteplase Value Set Request Created: 06/07/22 Updated: 06/10/22 Resolved: 06/10/22 |
|
| Status: | Closed |
| Project: | eCQM Issue Tracker |
| Component/s: | None |
| Type: | Hosp Inpt eCQMs - Hospital Inpatient eCQMs | Priority: | Moderate |
| Reporter: | Brooke Villarreal (Inactive) | Assignee: | Joelencia Leflore |
| Resolution: | Answered | Votes: | 0 |
| Labels: | None | ||
| Solution: | Thank you for your question about STK-5/eCQM 72v11, Antithrombotic Therapy By End of Hospital Day 2. The "Thrombolytic (t-PA) Therapy" (OID: 2.16.840.1.113883.3.117.1.7.1.226) value set utilizes the semantic clinical drug (SCD) concept. SCD codes are generalizeable drug concepts and each RxNorm clinical drug name reflects the active ingredients, strengths, and dose form comprising that drug.
Currently there are the only two generic, prescribable SCD codes for alteplase and smaller doses do not exist. If there are relevant updates to RxNorm we will consider adjustments to the value sets during the next Annual Update. |
| Solution Posted On: | |
| 2022 Reporting Period Hosp Inpt eCQMs: |
CMS0072v10
|
| Impact: | I would like to request the inclusion of smaller dose vials of alteplase to the STK-72 Thrombolytic (t-PA) Therapy value set. We have received feedback from facilities that Neuro Interventional Radiology does not typically carry the larger doses of alteplase because they are not required in this department. The use of the smaller dose vials is currently resulting in measure failure for some patients. Example dosages include 2mg vials, 1mg/mL injectable solution. |
| Comments |
| Comment by Joelencia Leflore [ 06/08/22 ] |
|
Thank you for submitting your question. We will review your ticket and provide a response as soon as possible. |